Form 4: BDX Executive Sells Shares Under 10b5-1 Plan

Becton Dickinson EVP Michael Feld sold 58 shares of common stock for $181.03 per share on September 26, 2025, under a pre-arranged 10b5-1 plan.

Summary

• Michael Feld, Executive Vice President and President of Life Sciences at Becton Dickinson & Co (BDX), reported a transaction involving the company's common stock.
• The transaction, dated September 26, 2025, involved the disposition of 58 shares of BDX common stock.
• The shares were sold at a price of $181.03 per share.
• Following this reported transaction, Michael Feld directly beneficially owns 8,302 shares of BDX common stock.
• This sale was conducted pursuant to a Rule 10b5-1 plan, which was adopted by Michael Feld on August 2, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a pre-planned insider stock sale under a Rule 10b5-1 plan, which typically does not reflect new discretionary sentiment about the company's prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This is a routine insider transaction report and does not provide information related to broader industry trends or competitors.

Stakeholder Impact

• Shareholders: Minimal impact due to the small volume of shares sold and the pre-planned nature of the transaction.

Key Dates

Keywords

Becton Dickinson, BDX, Michael Feld, Insider Transaction, Form 4, 10b5-1 Plan, Stock Sale, Executive